{"id":"NCT01508455","sponsor":"Hospira, now a wholly owned subsidiary of Pfizer","briefTitle":"Open-Label, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age","officialTitle":"A Phase II/III, Open-Label, Multicenter, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2012-03","primaryCompletion":"2012-05","completion":"2012-05","firstPosted":"2012-01-12","resultsPosted":"2013-12-11","lastUpdate":"2017-08-23"},"enrollment":6,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anesthesia"],"interventions":[{"type":"DRUG","name":"Dexmedetomidine","otherNames":[]},{"type":"DRUG","name":"Midazolam","otherNames":[]},{"type":"DRUG","name":"Fentanyl","otherNames":[]},{"type":"DRUG","name":"Morphine","otherNames":[]}],"arms":[{"label":"Dexmedetomidine","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to characterize the safety, and efficacy of Dexmedetomidine (DEX) administered as an intravenous (IV) loading dose followed by a continuous IV infusion in preterm subjects, ages ≥ 28 weeks through \\< 36 weeks gestational age.","primaryOutcome":{"measure":"Percent of Subjects Requiring Rescue Midazolam for Sedation","timeFrame":"During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).","effectByArm":[{"arm":"Dexmedetomidine","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"28 Weeks","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":["24238862"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":6},"commonTop":["Umbilcal hernia","Hypernatraenia","Blister"]}}